{"entity":{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","aka":[],"tldr":"Epidemiologist who showed HPV vaccination has nearly eliminated cervical cancer in vaccinated English women and leads NHS-Galleri.","summary":"Peter Sasieni led the 2021 Lancet analysis showing the English HPV vaccination programme cut cervical cancer by 87% in women vaccinated at 12-13, one of the clearest demonstrations of cancer prevention ever recorded, and the modelling that underpins HPV-based and extended-interval cervical screening. He co-leads the NHS-Galleri trial of multi-cancer early detection and directs the Cancer Prevention Trials Unit.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasieni%20P%5BAuthor%5D%20cervical%20screening%20HPV"}],"tags":["screening","hpv","prevention"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine","mced"],"targets":[],"drugs":["galleri"],"companies":[],"institutions":["barts-cancer-institute","cruk"],"pathways":[],"terms":[],"trials":["nhs-galleri"],"people":[],"bottlenecks":[],"keyPapers":["paper-hpv-vaccine-england-lancet-2021","paper-nhs-galleri-design-cancers-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Epidemiology, Queen Mary University of London; Director, Cancer Prevention Trials Unit","institutionId":"barts-cancer-institute","specialisms":["Cervical screening","HPV vaccination evaluation","Screening trial design","Cancer prevention epidemiology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sasieni%20P%5BAuthor%5D%20cervical%20screening%20HPV"}],"papers":[{"title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)02178-4"},{"title":"Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data","journal":"BMJ","year":2009,"doi":"10.1136/bmj.b2968"},{"title":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","journal":"Cancers","year":2022,"url":"https://doi.org/10.3390/cancers14194818","doi":"10.3390/cancers14194818"}],"orcid":"0000-0003-1509-8744"},"route":"/people/peter-sasieni/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"}],"institution":[{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/"},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"}],"trial":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/"}],"paper":[{"id":"paper-hpv-vaccine-england-lancet-2021","kind":"paper","name":"England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13","route":"/key-papers/paper-hpv-vaccine-england-lancet-2021/"},{"id":"paper-nhs-galleri-design-cancers-2022","kind":"paper","name":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","route":"/key-papers/paper-nhs-galleri-design-cancers-2022/"},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}